Back

Innate Pharma beats EPS estimates as Sobi partnership brings $75 million upfront payment

Verifying
  • Innate Pharma secured a strategic partnership with Sobi for lacutamab.
  • Innate Pharma reported EPS of -$0.24 and revenue of $6.5 million.
  • The company received a $75 million upfront payment from Sobi.
The information on this website is generated using AI and we cannot guarantee its accuracy. Please use it as reference information only.